Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million. The buy-out was part of a spending spree by Lilly on company pipelines that address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat. LimmaTech […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!